Nexlizet NDC 72426-818

NDC codes

FDA NDC Directory

Product NDC (as listed)72426-818Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72426-0818Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72426-818-03	72426081803	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-818-03)Marketed from Mar 9, 2020
72426-818-99	72426081899	7 TABLET, FILM COATED in 1 BLISTER PACK (72426-818-99)Marketed from Mar 9, 2020 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nexlizet
Generic name (nonproprietary): bempedoic acid and ezetimibe
Active ingredients: Bempedoic acid — 180 mg/1Ezetimibe — 10 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Esperion Therapeutics, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211617
Marketing start: Mar 9, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Adenosine Triphosphate-Citrate Lyase Inhibitors (Mechanism)Decreased Cholesterol Absorption (Physiologic effect)
Identifiers: Product ID 72426-818_29da37de-60f3-4dcc-8ccd-1b96631778bdSPL ID 29da37de-60f3-4dcc-8ccd-1b96631778bdSPL set ID 3fa2108c-0300-47b8-9d34-f762af7c93c6RxCUI 2283230, 2283236UNII 1EJ6Z6Q368, EOR26LQQ24
Pharmacologic class: Adenosine Triphosphate-Citrate Lyase Inhibitor; Dietary Cholesterol Absorption Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472426081803 followed by a unit qualifier and the quantity

Package 72426-0818-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 25, 2026.

Indications (excerpt from the label)

NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). NEXLIZET, a combination of bempedoic acid, an adenosine triphosphate citrate lyase (ACL) inhibitor, and ezetimibe, a dietary cholesterol absorption …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)